Lipid and brain volumetric measures in multiple sclerosis patients: findings from a large observational study.

Autor: Lorincz B; Department of Neurology, Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic., Vrablik M; Third Department of Internal Medicine, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic., Murali R; Department of Pharmaceutical Sciences and Neurology, University at Buffalo, State University of New York, Buffalo, NY, USA., Havrdova EK; Department of Neurology, Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic., Horakova D; Department of Neurology, Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic., Krasensky J; Department of Radiology, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic., Vaneckova M; Department of Radiology, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic., Uher T; Department of Neurology, Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic. tomas.uher@vfn.cz.
Jazyk: angličtina
Zdroj: Acta neurologica Belgica [Acta Neurol Belg] 2024 Dec; Vol. 124 (6), pp. 1981-1988. Date of Electronic Publication: 2024 Oct 25.
DOI: 10.1007/s13760-024-02676-w
Abstrakt: Objectives: This study aimed to investigate relationships between cholesterol profile, brain volumetric MRI, and clinical measures in a large observational cohort of multiple sclerosis (MS) patients.
Materials and Methods: We included 1.505 patients with 4.966 time points including complete lipid, clinical, and imaging data. The time among lipid, brain MRI and clinical measures was under 90 days. Cross-sectional statistical analysis at baseline was performed using an adjusted linear regression and analysis of longitudinal lipid and MRI measures data was performed using adjusted linear mixed models.
Results: We found associations between higher high-density lipoprotein cholesterol (HDL-C) and lower brain parenchymal fraction (BPF) at cross-sectional analysis at baseline (B = -0.43, CI 95%: -0.73, -0.12, p = 0.005), as well as in longitudinal analysis over follow-up (B = -0.32 ± 0.072, χ 2  = 36.6; p = < 0.001). Higher HDL-C was also associated with higher T2-lesion volume in longitudinal analysis (B = 0.11 ± 0.023; χ 2  = 23.04; p = < 0.001). We observed a weak negative association between low-density lipoprotein cholesterol (LDL-C) levels and BPF at baseline (B = -0.26, CI 95%: -0.4, -0.11, p = < 0.001) as well as in longitudinal analysis (B = -0.06 ± 0.03, χ 2  = 4.46; p = 0.03). T2-LV did not show an association with LDL-C. We did not find any association between lipid measures and disability. The effect of lipid levels on MRI measures and disability was minimal (Cohen f2 < 0.02).
Conclusions: Our results contradict the previously described exclusively positive effect of HDL-C on brain atrophy in patients with MS. Higher LDL-C was weakly associated with higher brain atrophy but not with higher lesion burden.
Competing Interests: Declarations. Disclosures: Balazs Lorincz received financial support for conference travel from Merck, Medtronic, Bayer and speaker honoraria from Sandoz. Manuela Vaneckova received speaker honoraria, consultant fees, and travel expenses from Biogen Idec, Novartis, Roche, Genzyme, and Teva, as well as support for research activities from Biogen Idec. Michal Vrablik reports fees for clinical trials, consultancy and presentations from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Mylan, Novartis, Novo Nordisk, Sanofi and Zentiva.  Murali Ramanathan received research funding from the National Science Foundation, the Department of Defense, and the National Institutes of Health. Elizabeth C Jury is supported by grants from the Dunhill Medical Trust (RPGF1902\117) and NIHR UCLH Biomedical Research Centre grant BRC772/III/EJ/101350 and Fast Track grant F215.  Jan Krasensky received financial support for research activities from Biogen Idec.  Eva Kubala Havrdova received speaker honoraria and consultant fees from Biogen Idec, Merck Serono, Novartis, Genzyme, Teva, Actelion, and Receptos, as well as support for research activities from Biogen Idec and Merck Serono.  Dana Horakova was supported by the Czech Ministry of Education project Progres Q27/LF1 and received compensation for travel, speaker honoraria, and consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche and Teva, as well as support for research activities from Biogen Idec. R.A. received speaker honoraria, advisory board fees, research support or conference travel support from Biogen, Merck, Sanofi, Roche and Novartis.  Tomas Uher received financial support for conference travel and honoraria from Biogen Idec, Novartis, Roche, Genzyme, and Merck Serono, as well as support for research activities from Biogen Idec and Sanofi. .
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: